According to numerous studies, more than 50% of malignant tumors are related to p53 (Vogelstein et al., 2000; Joerger and Fersht, 2007; Vazquez et al., 2008); hence, p53-MDMX/MDM2 interaction is an important target for tumor drugs. This evidence concerns the gene TP53 and cancer.